Dose accuracy and injection force dynamics of a novel disposable insulin pen

Comparisons between SoloStar and two commonly used pens, FlexPen® (Novo Nordisk) and the Humulin®/Humalog® pen (Eli Lilly) establish SoloStar as a state of the art pen that is suitable for most patients with diabetes.

Abstract

SoloStar (sanofi-aventis) is a new, disposable insulin pen for the administration of insulin glargine (Lantus, sanofi-aventis) or insulin glulisine (Apidra, sanofi-aventis). SoloStar was developed to address a wide range of patient needs and demonstrates advancement over previous devices, owing to its appropriate combination of ergonomically-tested and mechanically improved features. The authors report the results of key investigations carried out by sanofi-aventis as part of the SoloStar development plan, including dose accuracy and injection force testing. Comparisons between SoloStar and two commonly used pens, FlexPen (Novo Nordisk) and the Humulin/Humalog pen (Eli Lilly) establish SoloStar as a state of the art pen that is suitable for most patients with diabetes.